Bevacizumab与Iressa对高转移肝癌原位移植瘤血管形成的抑制作用

目的探讨Bevacizumab与Iressa对人高转移肝癌模型LCI-D20血管形成的抑制作用。方法动物模型制备7d后,分别采用空白对照Bevacizumab、Iressa以及二者联合治疗LCI-D20,用药28d后处死裸鼠,测量肿瘤质量,检测肿瘤组织微血管密度。结果裸鼠模型分为对照(A)组、Bevacizumab(B)组、Iressa(C)组、Bevacizumab与Iressa联合应用(D)组:各组平均瘤重分别为2.01、0.10、1.18、0.04g,A、B、C、D四组做完全随机方差分析,检验统计量F为42.81,P<0.01,A、B、C、D四组有统计学差异;A、B、C、D组做两两均数比较,AB、AC、AD、BC、CD均有差异,BD无差异。平均MVD为39.57、4.87、14.10、2.03人/HP,A、B、C、D四组做完全随机方差分析,检验统计量F为2283.65,P<0.01,A、B、C、D四组有统计学差异。结论血管形成抑制剂Bevacizumab与Iressa有抑制肝癌血管形成及肿瘤生长的活性;联合应用可提高疗效。

Anti-angiogenic effects of Becacizumab combined with Iressa in highly metastatic human liver carcinoma orthotopic xenografty: An experimental study

Objective To investigate the role of Becacizumab combined with Iressa on angiogenesis in the treatment of hepatocellular carcinoma of animal model (LCI-D20).Methods Nude mice model bearing orthotopic xenografty highly matastatic human HCC were made and random divided into 4 groups: controlled group (A group), Becacizumab group (B group), Iressa group (C group) and combination group (D group). At the 28 days after administration of drugs, the mice were put to death, then tumor-mass and microvessel density(MVD) were measured. Results The mean tumor mass was 2.01g,0.10g,1.18g,0.04g in A,B,C,D group respectively. The mean MVD was 39.57,4.87,14.10,2.03 in A,B,C,D group respectively. Bevacizumab and Iressa all reduced MVD of tumor vessels and tumor mass markedly as monotherapy(P<0.01).Conclusion Bevacizumab and Iressa all has the effectiveness to inhibit angiogenesis and tumor growth of LCI-D20 HCC in nude mice,and combination of both could increase therapeutic effects.